iiinova — where your digital self keeps evolving

Reposted by Robert Brown

Anuja Java @anujajava.bsky.social · 06/02/2026

As therapies for complement-mediated kidney disease evolve, infection prevention remains critical!!! We summarize current evidence, infectious risks & prevention strategies to support safe implementation in practice. @asnpublications.bsky.social journals.lww.com/cjasn/abstra...

journals.lww.com

031

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 12/09/2025

We need a good biomarker for IgAN given the impoartance of immunosuppression (vs non-specific therapies: RASi, Flozins, ERA) But the Gd-IgA doesn’t seem so impressive to me? journals.lww.com/cjasn/pages/... #NephSky @asnpublications.bsky.social #CJASN VA by @corinateodosiu.bsky.social

Visual abstract of the study from Corina

172

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/09/2025

How common is kidney failure with MCD and FSGS? More than we think … @brianrifkin.bsky.social breaks down the recent @asnpublications.bsky.social JASN paper from the RaDaR study www.nephjc.com/news/nephjc-...

2135

Reposted by Robert Brown

Jyoti Baharani @renalpages.bsky.social · 04/09/2025

🚨 Exciting Fellowships! 🚨 Join UHB NHS FT as a Clinical Research Fellow in Renal Medicine (12m fixed term, £65k, Birmingham). Apply now: 🧠 Dialysis & Cognition: jobs.nhs.uk/candidate/joba… 💉 Hypertension & Dialysis: jobs.nhs.uk/candidate/joba�� #Renal #Research

jobs.nhs.uk

073

Reposted by Robert Brown

barnyhole.bsky.social @barnyhole.bsky.social · 19/08/2025

Proud of this Kidney International paper: doi.org/10.1016/j.ki.... Nephrology involves optimal delivery of treatments that prolong life, preserve & replace organ function. The art lies in shaping this care to the person. @rachaelmorton.bsky.social @lucyselman.bsky.social @flissmurtagh.bsky.social

Figure 1 | Patients have diverse preferences that reflect individual variation in what they consider important. Those planning for life
with kidney failure want control over their futures and tend to desire autonomy in treatment decision-making. They will trade off the
potential benefits of treatments against an over-riding desire to minimize disruption of daily and family life, responsibilities, and interests. The
treatments that patients plan for and receive reflect complex processes involving many actors. Familial, community, societal, cultural,
spiritual, clinical, and informational factors shape preferences, restrict or provide treatment options, and guide decisions. Skill, investment,
and intentional practice are needed to ensure that patient preferences carry weight in decision-making.

075

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/07/2025

Vitamin R + Cyclophosohamide in ANCA vasculitis A case series from Edinburgh suggesting this allows faster steroid withdrawal? @kireports.bsky.social www.kireports.org/article/S246... #NephSky #Vasculitis

Figure 2 (a) Kidney response to treatment. Scatter plots of individual change in eGFR at 12 months versus baseline eGFR, stratified by duration of glucocorticoid therapy, and (b) individual change in uPCR at 12 months versus baseline uPCR for the whole cohort. r values are Pearson coefficients. Alluvial plots demonstrating change in AAV classification from initial biopsy to interval biopsy (n = 19) for (c) Berden classification, and (d) ANCA Kidney Risk Score. AAV, antineutrophil cytoplasm antibody-associated vasculitis; ANCA, antineutrophil cytoplasm antibody; eGFR, estimated glomerular filtration rate; uPCR, urinary protein-to-creatinine ratio.

132

Reposted by Robert Brown

Gunnar Heine @gunnarheine.bsky.social · 26/07/2025

Few drugs would be licensed with a > 5 % risk of liver enzyme level elevation - why are law makers so lenient with cannabidiol? jamanetwork.com/journals/jam...

262

Reposted by Robert Brown

Christos Argyropoulos MD, PhD, FASN 🇺🇸 0kale/acc @christosargyrop.bsky.social · 09/07/2025

Only reason to sequence the RASi first is that they are good antihypertensives (but note the BP effect in the combo arm of #confidence) #nephjc But no matter the sequence, the goal should be to have someone on the four pillars in less than 6 months

1116

Reposted by Robert Brown

Brendon Neuen @brendonneuen.bsky.social · 15/07/2025

SGLT2i in CKD: impact beyond kidneys 🔻 15% all-cause hospitalizations ✅ Consistent regardless of eGFR, UACR & diabetes 🏥 ~36 fewer hospitalizations per 1000 pt-years Large absolute gains for patients & health systems Meta-analysis in @asnpublications.bsky.social journals.lww.com/cjasn/pages/...

11310

Reposted by Robert Brown

Nephrology Journal Club @nephjc.bsky.social · 16/07/2025

1/10 Last #NephJC we discussed the combination therapy of empagliflozin and finerenone 💊 #TenPostNephJC 🌵From a therapeutic dessert to a flood of options in diabetic kidney disease (DKD) - what is the best timing to keep the kidneys afloat

1107

Reposted by Robert Brown

Nephrology Journal Club @nephjc.bsky.social · 09/07/2025

T0b: #NephJC In DKD, the residual risk with flozins added to RASi, still remains high. We need every option in the arsenal, if we hope for better outcomes. So, here are the 4 pillars of modern cardio-renal therapy: medicinetoday.com.au...

186

Reposted by Robert Brown

Kidney Care UK @kidneycareuk.bsky.social · 07/07/2025

🖊️ Do you feel #KidneyDisease is overlooked? It’s time to act. Sign our open letter to the Prime Minister calling for a national #CKDstrategy & a better future for kidney patients 👉 www.ukkidney.org/prime-minist... @Kidney_Research @kidneycareuk @NKF_UK @PKDCharity @UKKidney

A letter with visible logos of Kidney Care UK, Kidney Research UK, PKD Charity, UK Kidney Association and The National Kidney Federation at the bottom, addressing important health policy commitments.

012

Reposted by Robert Brown

Jyoti Baharani @renalpages.bsky.social · 20/06/2025

🧠 New publication latent TB screening in CKD 📈 TB incidence in UK dialysis patients > some high-burden countries, yet national screening guidance unclear. We call for equitable access 👉 : doi.org/10.1093/ckj/... #Nephrology #TB #CKD #LTBI #PublicHealth #Dialysis #HealthEquity #MigrationHealth

175

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 07/06/2025

Huge Danish trial of nudges Patient level (N 22,000) + practice level (1500 practice cluster with N 28,000 pts) To increase RASination & Flozination www.ahajournals.org/doi/abs/10.1... in @ahajournals.bsky.social at #ERA25 Absolutely null effect - is the baseline too high to improve upon?

4158

Reposted by Robert Brown

American Journal of Kidney Diseases @ajkd.bsky.social · 03/06/2025

Core Curriculum by @nephcrit.bsky.social , @hswapnil.medsky.social , Abdulghani Omar Kabli, Oleksa G. Rewa, and Edward G. Clark: Continuous Kidney Replacement Therapies: Core Curriculum 2025 bit.ly/TeixeiraCC25 (FREE)

084

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 02/06/2025

Foundational therapies in ESRD for heart failure Dr Matt Graham-Brown from Leicester presents at #NephGR www.youtube.com/watch?v=Ar11... (Rounds from Feb, late share!)

youtube.com

Foundation therapies for heart failure in end stage kidney disease with Dr Matt Graham-Brown

YouTube video by Ottawa Nephrology

092

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 12/05/2025

There you have it: BEDMED published in @jama.com jamanetwork.com/journals/jam... h/t @drjmluther.bsky.social No difference in bedtime versus morning BP meds - as expected #NephSky #Hypertension 1/

Figure of survival curve showing no difference

25628

Reposted by Robert Brown

ASN Publications @asnpublications.bsky.social · 23/05/2025

Genetic mutations in the terminal complement system may lead to increased susceptibility to preeclampsia. Targeting the terminal complement pathway could be a potential therapeutic strategy. bit.ly/KN1705-19 @silvishah.bsky.social #ASNKidneyNews

075

Reposted by Robert Brown

UK Kidney Association @ukkidney.org · 21/05/2025

📢 New @RenalRadar paper! The study explores how nephrotic syndrome progresses & the link between proteinuria & kidney failure risk. 🔍 Insights will help clinicians identify higher risk patients earlier & improve clinical trial design. Read more 👉 ow.ly/xVyz50VTPQP

031

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 14/05/2025

The ADPKD @kdigo.org guideline episode of @freelyfiltered.bsky.social www.nephjc.com/freelyfilter... Joel, Nayan, AC, with Sophia Ambruso coining a new word for posting here (bleat!) And Charles Edelstein dropping lot of wisdom + @rheaultm.bsky.social with a cameo #NephSky

nephjc.com

FF 80 KDIGO ADPKD Guidelines — NephJC

Yet another KDIGO Guideline draft, this one for ADPKD

0146

Reposted by Robert Brown

UK Kidney Association @ukkidney.org · 13/05/2025

💡New SPOTLIGHT ✨ As part of our 75th celebrations, we're featuring the AKI SIG — a powerhouse of collaboration. From mapping UK AKI services to developing the world’s first AKI Master Patient Index, the group is transforming #AKICare👏 Explore more about the SIG's work: www.ukkidney.org/75-...

022

Reposted by Robert Brown

Lucy Selman @lucyselman.bsky.social · 13/05/2025

📣 New paper now online @ckj-era.bsky.social: How do patient information documents present dialysis and conservative kidney management? A document analysis. academic.oup.com/ckj/advance-... @flissmurtagh.bsky.social @peolcsw.bsky.social @wolfsonpallcare.bsky.social @danafarber.bsky.social

Paper infographic about how patient information documents frame dialysis and conservative kidney management in inaccurate ways.

156

Reposted by Robert Brown

Helen Hương Kilminster @hpillminster.pharmsky.app · 10/05/2025

Great to hear some further detail from @rpharms.com professional liability insurance. Currently 3-yr cover retrospective cover, AON challenged by audience member, consideration for a possible change. Nice one Ishaq! 😉 Run off built in!!! Indefinitely!!!! No additional charge. #CPCongess #PharmSky

042

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 10/05/2025

Dapagliflozin in non-diabetic CKD with low/high ACR - OPTIMISE CKD observational design Pretty flat GFR slopes? academic.oup.com/ckj/article/... on @ckj-era.bsky.social #NephSky #OpenAccess

Figure 2:eGFR change from baseline over time following dapagliflozin initiation in patients with CKD without type 2 diabetes in the USA in the years 2021–23 (post-approval). *Initiation of dapagliflozin 10 mg.

2124

Reposted by Robert Brown

Cathy Pogson @cathypogson.bsky.social · 11/05/2025

Fabulous couple of days @cpcongress.bsky.social presenting my present bpspubs.onlinelibrary.wiley.com/doi/10.1111/... and future research plans www.kidneyresearchuk.org/2025/04/22/p... & with UK Renal Pharmacy preventing progression to end stage kidney disease @kidneyresearchuk.org @ukkidney.org

043

Reposted by Robert Brown

Cristina Popa @nephroseeker.medsky.social · 05/05/2025

It doesn’t take long, only takes 10-15 min

031

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 26/04/2025

The illegal kidney transplant trade continues Now centered in Kenya, with donors from Africa, Azerbaijan and elsewhere Recipients from Western Europe, Russia, and other places www.spiegel.de/internationa... With an Indian in the center #NephSky #PublicHealth h/t @jbrianbyrd.bsky.social

spiegel.de

Organ Trafficking: How Germans Buy New Kidneys in Kenya

Germans in need of new kidneys are heading to Kenya to buy one. The donors are frequently suffering from bitter poverty. Behind the scheme is an Israeli whom the authorities have been after for years.

31313

Reposted by Robert Brown

Dr. Hardik Patel 🩺💉 @hardik4u24.bsky.social · 26/04/2025

💉Immune checkpoint inhibitors: 🦸‍♂️heroes in cancer🦀, 🦹‍♂️villains for kidneys 🫘? #ICI-AKI can hit both Glomeruli (C3GN, MCD, vasculitis) & Tubulointerstitium (ATIN, ATN, tubulitis) 📖 doi.org/10.34067/KID... 🆕 @asnpublications.bsky.social K360 #Onconephrology #Nephrology #AKI #NephSky #NephPearls

063

Reposted by Robert Brown

David Hettle @david-hettle.bsky.social · 22/04/2025

Look after patients with neonatal sepsis in sub-Saharan Africa? 🫵We want to hear from YOU! ❓Why❓ Exploring clinicians experiences of diagnostics, antibiotics + guidelines 📢 English, French or Portuguese 🔗 redcap.sun.ac.za/surveys/?s=N9A…

112

Reposted by Robert Brown

Chris Hill @dochill1982.bsky.social · 18/04/2025

In 2009 as a nephrology trainee I asked a wise old nephrologist what his practice was regarding CKD-MBD as I was confused. His reply “well Chris I mostly ignore it unless the values are awful because there isn’t a shred of evidence for any of it…” Turns out he’s still right!

073

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 14/04/2025

Couple of mock examples for illustration from two extremes #NephSky #PharmSky #EMIMCC

1112

Reposted by Robert Brown

josh farkas 💊 @pulmcrit.bsky.social · 14/04/2025

just learned this & mind blown 🤯 CKD-EPI, MDRD etc give us GFR corrected for body surface area (ml/min/1.73m2) BUT we're supposed to use the *absolute* GFR (ml/min) for drug dosing (eg KDIGO 2024 guidelines below; FDA agrees) in obesity, the computer's ml/min/1.73m2 can be way too low #EMIMCC

63312

Reposted by Robert Brown

Nephrology Journal Club @nephjc.bsky.social · 16/04/2025

T0b: During the last decades, metformin keeps proving it's more than just a glucose fixer—it's weight-neutral, heart-friendly, and quietly doing the most behind the scenes #NephJC Adapted from link.springer.com/ar...

2297

Reposted by Robert Brown

Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 16/04/2025

Stopping vs. Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study ca. 2025 from @ajkd.bsky.social #Nephpearls #NephJC #NephSky #VisualAbstract by @nephroseeker.medsky.social 👉 pubmed.ncbi.nlm.nih.gov/39521399/

1259

Reposted by Robert Brown

Joel Topf @kidneyboy.bsky.social · 11/04/2025

What's C3G It is not a new disease But the term C3 glomerulopathy was accepted in 2013 #NKFClinicals

172

Reposted by Robert Brown

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 10/04/2025

Ultra rapid prednisone taper (median 14 days!) in ANCA vasculitis from the Imperial group www.kireports.org/article/S246... in @kireports.bsky.social #NephSky

1124